Skip to main content
An official website of the United States government

alnuctamab

A bispecific T-cell engager (BiTE) antibody directed against both the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, alnuctamab binds bivalently to BCMA expressed on tumor cells and monovalently to CD3 expressed on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to BCMA-expressing tumor cells, which results in the CTL-mediated death of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.
Synonym:ALNUC
anti-BCMA/CD3 bispecific antibody CC-93269
BCMA x CD3 T cell-engaging antibody CC-93269
BCMA/CD3 T-cell bi-specific antibody CC-93269
BCMA/CD3-directed bispecific T-cell engager antibody CC-93269
BCMAxCD3 BiTE antibody CC-93269
BCMAxCD3 TCB CC-93269
bi-specific antibody CC-93269
Code name:BMS 986349
BMS-986349
BMS986349
CC 93269
CC-93269
CC93269
Search NCI's Drug Dictionary